In 1969, the anticancer effect of CP was evaluated in the sarcoma mouse model (Rosenberg et al., 1969), and by 1971, CP had entered phase I clinical trials and was finally approved by the US Food and Drug Administration for the management of cancers in 1978 (Andrea and Reddy, 2018). The gene discussed is CP; the disease is sarcoma.